AMENDMENTS TO THE CLAIMS

This **listing of claims** will replace all prior versions, and listings, of the claims in the application.

Listing of Claims

1-144. (canceled)

145. (currently amended) A method of treating a transplant recipient or preventing transplant rejection in a transplant recipient, comprising administering to the recipient an effective amount of a[[n]] humanized immunoglobulin specific to B7-1, and an effective amount of a immunoglobulin specific to B7-2, wherein the humanized immunoglobulin specific to B7-1 comprises a constant region of human origin and a variable region, wherein said variable region comprises:

a) one or more complementarity determining regions derived from the 1F1 mouse monoclonal antibody (ATCC Accession No. PTA 263) and

b) one or more framework regions of human origin

~~further including administering an agent selected from the group consisting of: calcineurin inhibitor, steroid, immunosuppressive agents that arrest the growth of immune cells, methotrexate, transplant salvage pathway inhibitor, IL-2 receptor antagonist, and analogs thereof and wherein an anti-CD40 antibody or anti-CD40 ligand antibody are not administered to the transplant recipient~~.

146. (canceled)

147. (currently amended) The method of Claim 145, ~~wherein~~ further comprising the step of administering cyclosporin A or FK506 to the recipient ~~is administered~~.

148. (canceled)

149. (currently amended) The method of Claim 145, ~~wherein~~ further comprising the step of administering rapamycin to the recipient ~~is administered~~.

150. (previously presented) The method of Claim 145, wherein the immunoglobulin specific to B7-1 is administered in an amount between about 1 mg/kg and about 25 mg/kg, and the immunoglobulin specific to B7-2 is administered in an amount between about 1 mg/kg and about 25 mg/kg.

151. (previously presented) The method of Claim 150, wherein the immunoglobulin specific to B7-1 and the immunoglobulin specific to B7-2 are administered on the day the recipient receives the transplantation.

152. (currently amended) The method of Claim 149, wherein the humanized immunoglobulin specific to B7-1 and the ~~humanized~~ immunoglobulin specific to B7-2 are further administered periodically after the recipient receives the transplantation.

153. (currently amended) The method of Claim 152, wherein the humanized immunoglobulin specific to B7-1 is administered between about 1 mg/kg and about 5 mg/kg, and the ~~humanized~~ immunoglobulin specific to B7-2 is administered between about 1 mg/kg and about 5 mg/kg at least weekly after the recipient receives the transplantation.

154-160. (canceled)

161. (new) The method of claim 145, wherein the immunoglobulin specific to B7-2 is a humanized immunoglobulin that has a binding affinity for B7-2 of at least about 10^7 M^{-1}, and wherein the immunoglobulin specific to B7-2 comprises an antigen binding region of non-human origin and at least a portion of an immunoglobulin of human origin, further wherein the antigen binding region of non-human origin comprises at least one framework region containing a substitution of at least one amino acid in the III2R heavy chain framework region or the H2F light chain framework region.

162. (new) A method of treating a transplant recipient or preventing transplant rejection in a transplant recipient, comprising administering to the recipient an effective amount of an immunoglobulin specific to B7-1, and an effective amount of a humanized immunoglobulin specific to B7-2, wherein the humanized immunoglobulin specific to B7-2 has a binding affinity of at least about 10^7 M^{-1}, and wherein said immunoglobulin comprises at least a portion of an immunoglobulin of human origin, further wherein the antigen binding region of non-human origin comprises at least one framework region containing a substitution of at least one

amino acid to a corresponding amino acid in the heavy chain framework region of the III2R antibody (SEQ ID NOS: 45, 49) or the light chain framework region of the H2F antibody (SEQ ID NOS: 46, 50), and wherein treatment of the autoimmune disease occurs.

163. (new) The method of Claim 162, further comprising the step of administering cyclosporin A or FK506 to the recipient.

164. (new) The method of Claim 145, further comprising the step of administering rapamycin to the recipient.